Morgan Stanley lowered the firm’s price target on Cytek Biosciences (CTKB) to $4 from $7 and keeps an Equal Weight rating on the shares post the Q2 report. The firm says recurring revenue strength offset weakness in the company’s instrument segment. It believes Cytek’s visibility remains limited.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTKB:
- Cytek Biosciences Earnings Call Reveals Mixed Outlook
- Cytek Biosciences: Q2 2025 Financial Performance Overview
- Cytek Biosciences Faces Market Challenges and Uncertain Growth Prospects Leading to Hold Rating
- Cytek Biosciences reports Q2 EPS (4c), consensus (1c)
- Cytek Biosciences narrows FY25 revenue view to $196M-$200M from $196M-$210M